Clinical progress, corporate developments, partnerships, and media coverage.
A strategic MOU combining an AI drug-discovery platform with international manufacturing, regulatory, and market-access resources to drive new drugs from clinical development to global commercialization.
Source: Economic Daily
FPT-001 has cleared the Australian CTN and obtained Phase II approval — a key milestone; FPT-003 is also advancing international licensing in parallel.
Source: Economic Daily
Lead product FPT-001 has submitted its Phase II CTN application to an Australian HREC, formally launching the company's international clinical program.
Source: Economic DailyRecognized for breakthrough pharmaceutical R&D, the company received this year's National Innovation Award (Startup category).
Source: Economic Daily
A new funding round closed with strong strategic-investor backing. Proceeds will fund preclinical research and trial preparation, targeting FDA IND clearance in Q1 2026.
Source: Economic DailyEffective Aug 28, 2025, the company's issued common shares are fully converted to book-entry form held under shareholders' names at the central depository.
Thank you to every shareholder for your participation and support — your feedback drives us forward.
Source: Company notice
Future PharmaTech earned Dun & Bradstreet (D&B) enterprise certification, raising credibility and international recognition.
Source: D&B certification
Developed via the 505(b)(2) pathway to accelerate entry into the men's-health and urology specialty market.
Source: Taiwan Healthcare Expo
Entering Phase II next year, with potential to compete in the global market.
Source: Economic Daily
Focused on dementia therapy development, bringing new hope to patients.
Source: GeneOnline Monthly